Resources

Cutaneous T Cell Lymphoma CTCL
Cutaneous T Cell Lymphoma CTCL

Working for a full-service market research company working with a clinical-stage biotechnology company focused on development of therapeutic antibodies for improvement in cancer treatment, M3 Global Research was seeking to secure “payers” to participate in the research focused on Cutaneous T Cell Lymphoma (CTCL). Learn more by reading this case study.

GDPR Update
M3 Global Research GDPR Update (20 June 2018)

There remain some important unanswered questions for the market research industry following the introduction of GDPR. Quality and compliance are fundamental to the M3 Global Research approach, and many clients have asked us to share our viewpoint on these important topics.

France Profile
Haemophilia

Haemophilia is a bleeding disorder in which clotting factor defi ciencies lead to bleeding in various areas of the body, with the most common types of bleeds being into the joints and muscles. Learn more about Haemophilia by reading our latest therapeutic review sheet.

France Profile
France

The population of France has experienced marginal year-over-year growth for decades, while wealth has risen, leading to a highly developed country with a stable population model. Learn about France's healthcare in this country profile.

Verification Process
M3 Verification Process

Data quality is of the utmost importance at M3 Global Research. To ensure the best possible quality, M3 uses a three-step-verification process before, during, and after a market research study. Read our Verification Overview to learn more.

HOW WE’RE KEEPING YOUR DATA SAFE
GDPR: How We're Keeping Your Data Safe

At M3 Global Research, we take data protection seriously. The General Data Protection Regulation is now in effect, and we’ve got it covered. Here are just some of the things we are doing to keep your data safe.

Meet our DPO
DPO: Do You Need One? Meet Ours!

With the deadline for implementing the EU’s General Data Protection Regulation (GDPR) fast approaching, your company may be trying to determine if you need a designated data protection officer (DPO).

GDPR Checklist
GDPR Checklist

General Data Protection Regulation (GDPR) will go into effect on 25 May, 2018 across the European Union. We’ve assembled this checklist to help you prepare.

M3 Global Research Overview
M3 Global Research Overview

Learn more about M3 Global Research's experience and capabilities in our "at a glance" overview.

GDPR Overview
GDPR Overview

General Data Protection Regulation (GDPR) will go into effect on 25 May, 2018 across the European Union.

Japan Profile
Japan

Over the last twenty years, Japan’s healthcare spending has been on the rise and this trend is expected to continue. A fast-growing, aging population and increasing cases of chronic diseases make Japan a long-term growth market for pharmaceutical companies. Between 2014 and 2018, healthcare spending is expected to rise by an average of three percent a year, reaching around 10 percent of GDP by the end of 2018.

2017 Review
2017 Review

Check our 2017 M3 review by the numbers.

Cataract
Deerfield Institute Publishes Paper on Ovarian Cancer that Mentions M3 Global Research

M3 Global Research client Deerfield Institute has had a paper on ovarian cancer published by Dove Medical Press, which details how M3 Global Research was used in Europe to contact medical and gynecologic oncologists.

Cataract
Cataract

M3 is active in recruiting for our client’s studies in the ophthalmology disease area. In 2016, we recruited over 13,000 respondents across 35 countries, for almost 100 studies and >50 clients. Most (68) were online quantitative surveys, 17 were qualitative only projects, and 11 included both study type activities.

Cystic Fibrosis
Cystic Fibrosis

M3 is active in recruiting for our client’s studies in the pulmonary and pediatric disease area. In 2016, we recruited over 14,000 respondents for >220 studies with >150 clients across 67 countries. Most (143) were online quantitative surveys, 63 were qualitative only projects, and 16 included both study type activities. Cystic Fibrosis was the primary topic area in 9 studies among >725 respondents in 12 countries.

IBS
Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) is a complex, poorly understood condition which is estimated to affect up to 15% of the US population. The condition primarily affects women, but up to 25% of the ~30 million sufferers are men. IBS is frequently divided into three segments depending on the patients symptoms: IBS-C (constipation dominant), IBS-D (diarrhea dominant), and IBS-mixed (both constipation and diarrhea).

Renal Disease
Renal Disease

In 2016, nearly 5,000 physicians who treat renal disease participated in 78 research studies across 14 countries with M3. Most (45) were online quantitative surveys, 27 were qualitative only projects, and 8 were for both study type activities.

2016 Review
2016 Review

Check our 2016 M3 review by the numbers.

Cardiovascular Disease
Cardiovascular Disease

M3 is active in recruiting for our client’s studies in the Cardiology space. In 2015, we recruited almost 21,000 healthcare professionals for over 230 studies across 20 or more countries. Surveys were completed primarily among hospital and nonhospital- based physicians in the Cardiologists / Cardiac Surgeons and Primary Care specialties.

Thyroid Disease
Thyroid Disease

M3 is active in recruiting for our client’s studies addressing the myriad issues and disease areas seen by Endocrinologists. In 2015 M3 studies alone, endocrinologists completed over 1,000 surveys across 50 plus studies and 24 countries.

Mobile App photo
ESOMAR 28 Questions

At M3 we diligently answer ESOMAR 28 questions to ensure your project is carried out meeting your quality requirements for online samples.

Mobile App photo
M3 CONFERENCE MOBILE APP

Our client was interested in helping their Pharma client gauge insight and reaction ‘in the moment’ to five specific abstracts or oral sessions, and conducting immediate response research with attendees soon after specific sessions ended.

MULTI-COUNTRY QUALITATIVE RESEARCH STUDY
MULTI-COUNTRY QUALITATIVE RESEARCH STUDY

M3 built on its extensive experience recruiting oncologists worldwide and expanded into a related audience in the community. The combined effort across US and EU M3 offices with local partners resulted in the successful recruitment of 50 leaders of patient advocacy groups across 28 countries.

DIABETES
DIABETES

M3 is actively engaged in recruiting physicians, patients, and ancillary care providers within this therapeutic space.

MULTI-COUNTRY QUALITATIVE RESEARCH STUDY
Medical Conditions with New Product Needs

With over 12 years' experience in the industry, M3 is the US leader among digitally active specialty HCPs and is the owner/operator of leading award winning HCP brands. M3 is actively engaged with 14 of the top 15 pharma companies & provides extensive coverage of EU20 physicians.

MULTI-COUNTRY QUALITATIVE RESEARCH STUDY
AMA Policy Research Perspectives: Updated Data on Physician Practice Arrangements

Inching Toward Hospital Ownership, offers four viewpoints on the practice arrangements of physicians in 2014, and the practice changes that have taken place between 2012 and 2014.

MULTI-COUNTRY QUALITATIVE RESEARCH STUDY
AMA Policy Research Perspectives: How are Physicians Paid?

A detailed Look at the Methods Used to Compensate Physicians in Different Practice Types and Specialties, provides a detailed look at how physicians are paid by their practices.


M3 is a proud member and supporter of